Balazs Meresz
Research Subjects
Balazs Meresz has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Tamas Atlasz
Department of Anatomy, HUN-REN-PTE PACAP Research Team, Medical School, University of Pecs, 7624 Pecs, Hungary
3 shared publications - Dora Reglodi
HUN REN-PTE PACAP Research Group, Department of Anatomy, University of Pecs Medical School, 7624 Pecs, Hungary
2 shared publications - Dorottya Molitor
Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Szigeti Str. 12, H-7624 Pecs, Hungary
2 shared publications - Evelin Patko
Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, Medical School, University of Pecs, 7624 Pecs, Hungary
2 shared publications Alexandra Vaczy
Affiliation Department of Anatomy, HUN-REN-PTE PACAP Research Team, Centre for Neuroscience, University of Pecs Medical School, Pecs, Hungary
1 shared publication- Alexandra Vaczy
HUN REN-PTE PACAP Research Group, Department of Anatomy, University of Pecs Medical School, 7624 Pecs, Hungary
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0353866
PAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation
Ocular inflammation is a leading cause of visual impairment and blindness worldwide. Systemic bacterial infections can spread hematogenously, resulting in endogenous endophthalmitis. These infections present significant diagnostic and therapeutic challenges due to their systemic origin and involvement of multiple ocular structures such as the retina and cornea. Pituitary adenylate cyclase-activating polypeptide (PACAP), acting through its selective receptor PAC1, exerts potent anti-inflammatory, anti-edema, and regenerative effects in various ocular conditions. This study aimed to assess the protective role of maxadilan, a selective PAC1 receptor agonist, in reducing corneal inflammation in a mouse model of lipopolysaccharide (LPS) -induced ocular inflammation. Mice received systemic LPS injections followed by intravitreal administration of maxadilan. Animals were monitored in vivo using optical coherence tomography (OCT) and tonometry. Post-mortem analyses included evaluation of cytokine expression profiles and routine corneal histological assessment. OCT revealed significantly reduced corneal edema and improved tissue structure with maxadilan administration. Additionally, maxadilan lowered intraocular pressure and reduced inflammatory cell infiltration into the aqueous humor. Cytokine profiling showed decreased expression of critical pro-inflammatory mediators such as GM-CSF, IL-6, MIP-1a, TNF-a, and TREM-1 in the maxadilan-treated group. Histological analyses confirmed that maxadilan preserved normal corneal architecture and effectively prevented pathological keratinization compared to untreated controls. These findings suggest that PAC1 receptor activation has therapeutic potential for controlling inflammation and maintaining corneal health in ocular inflammation.
- 20 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0353866
Open AccessPAC1 receptor agonist maxadilan alleviates corneal inflammation in a murine model of LPS-induced ocular inflammation
Ocular inflammation is a leading cause of visual impairment and blindness worldwide. Systemic bacterial infections can spread hematogenously, resulting in endogenous endophthalmitis. These infections present significant diagnostic and therapeutic challenges due to their systemic origin and involvement of multiple ocular structures such as the retina and cornea. Pituitary adenylate cyclase-activating polypeptide (PACAP), acting through its selective receptor PAC1, exerts potent anti-inflammatory, anti-edema, and regenerative effects in various ocular conditions. This study aimed to assess the protective role of maxadilan, a selective PAC1 receptor agonist, in reducing corneal inflammation in a mouse model of lipopolysaccharide (LPS) -induced ocular inflammation. Mice received systemic LPS injections followed by intravitreal administration of maxadilan. Animals were monitored in vivo using optical coherence tomography (OCT) and tonometry. Post-mortem analyses included evaluation of cytokine expression profiles and routine corneal histological assessment. OCT revealed significantly reduced corneal edema and improved tissue structure with maxadilan administration. Additionally, maxadilan lowered intraocular pressure and reduced inflammatory cell infiltration into the aqueous humor. Cytokine profiling showed decreased expression of critical pro-inflammatory mediators such as GM-CSF, IL-6, MIP-1a, TNF-a, and TREM-1 in the maxadilan-treated group. Histological analyses confirmed that maxadilan preserved normal corneal architecture and effectively prevented pathological keratinization compared to untreated controls. These findings suggest that PAC1 receptor activation has therapeutic potential for controlling inflammation and maintaining corneal health in ocular inflammation.
- Open Access
- 16 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3753
The Protective Effect of Topical PACAP38 in Retinal Morphology and Function of Type 2 Diabetic Retinopathy
The continuously growing diabetes population is a significant concern with type 2 diabetic retinal disease (T2DRD), which is a leading cause of permanent blindness. However, the underlying pathophysiological mechanism of T2DRD has not yet been fully understood. Pituitary adenylate cyclase-activating polypeptide (PACAP) was first isolated from the ovine hypothalamus based on its stimulating effect on the adenylate cyclase enzyme in anterior pituitary cells. PACAP38 (PACAP with 38 amino acids) activates anti-apoptotic pathways, inhibits pro-apoptotic signaling, and creates an anti-inflammatory environment in the retina. The aim of the present study was to test the possible retinoprotective effect of the topical administration of PACAP38 in a type 2 diabetic animal model induced by a high-fat diet and the intraperitoneally injected low-dose streptozotocin (STZ). Wistar rats were divided into four groups: the control, control + PACAP38, diabetes, and diabetes + PACAP38 groups randomly. Type 2 diabetes was induced with the combination of STZ (30 mg/kg) and a high-fat diet. All rats were treated topically two times a day for 16 weeks: the control + PACAP38 and diabetes + PACAP38 groups were applied with PACAP38 eye drops (1 µg/drop), while the control and diabetes groups were administered using vehicles (artificial tears). The diabetes model was validated by a fasting oral glucose tolerance test (OGTT) and C-peptide ELISA test. Animals were monitored during the whole experiment for the progression of the disease using electroretinography (ERG) and optical coherence tomography (OCT). Post-mortem immunohistochemistry and a vessel analysis were performed in the retina samples after 16 weeks. An OGTT, a C-peptide ELISA test, and the investigation of blood parameters proved the development of type 2 diabetes. Significant differences could be detected in visual function between the two diabetic groups at week 16 (in the a-wave, b-wave, and OP amplitudes), where the diabetes PACAP38-treated group was similar to the control ones. OCT measurements correlated with ERG data, where the total retinal thickness was preserved in the diabetes + PACAP38 group. PACAP38 also protected the microvascular structure in the retina. Topically administered PACAP38 has potent neuroprotective effects against type 2 diabetic retinal disease; therefore, it could be a promising therapeutic approach for the treatment of T2DRD.
- 16 April 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (8) , 3753
Open AccessThe Protective Effect of Topical PACAP38 in Retinal Morphology and Function of Type 2 Diabetic Retinopathy
The continuously growing diabetes population is a significant concern with type 2 diabetic retinal disease (T2DRD), which is a leading cause of permanent blindness. However, the underlying pathophysiological mechanism of T2DRD has not yet been fully understood. Pituitary adenylate cyclase-activating polypeptide (PACAP) was first isolated from the ovine hypothalamus based on its stimulating effect on the adenylate cyclase enzyme in anterior pituitary cells. PACAP38 (PACAP with 38 amino acids) activates anti-apoptotic pathways, inhibits pro-apoptotic signaling, and creates an anti-inflammatory environment in the retina. The aim of the present study was to test the possible retinoprotective effect of the topical administration of PACAP38 in a type 2 diabetic animal model induced by a high-fat diet and the intraperitoneally injected low-dose streptozotocin (STZ). Wistar rats were divided into four groups: the control, control + PACAP38, diabetes, and diabetes + PACAP38 groups randomly. Type 2 diabetes was induced with the combination of STZ (30 mg/kg) and a high-fat diet. All rats were treated topically two times a day for 16 weeks: the control + PACAP38 and diabetes + PACAP38 groups were applied with PACAP38 eye drops (1 µg/drop), while the control and diabetes groups were administered using vehicles (artificial tears). The diabetes model was validated by a fasting oral glucose tolerance test (OGTT) and C-peptide ELISA test. Animals were monitored during the whole experiment for the progression of the disease using electroretinography (ERG) and optical coherence tomography (OCT). Post-mortem immunohistochemistry and a vessel analysis were performed in the retina samples after 16 weeks. An OGTT, a C-peptide ELISA test, and the investigation of blood parameters proved the development of type 2 diabetes. Significant differences could be detected in visual function between the two diabetic groups at week 16 (in the a-wave, b-wave, and OP amplitudes), where the diabetes PACAP38-treated group was similar to the control ones. OCT measurements correlated with ERG data, where the total retinal thickness was preserved in the diabetes + PACAP38 group. PACAP38 also protected the microvascular structure in the retina. Topically administered PACAP38 has potent neuroprotective effects against type 2 diabetic retinal disease; therefore, it could be a promising therapeutic approach for the treatment of T2DRD.
- Open Access
- 23 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8008
Optimization of an Ischemic Retinopathy Mouse Model and the Consequences of Hypoxia in a Time-Dependent Manner
The retina is one of the highest metabolically active tissues with a high oxygen consumption, so insufficient blood supply leads to visual impairment. The incidence of related conditions is increasing; however, no effective treatment without side effects is available. Furthermore, the pathomechanism of these diseases is not fully understood. Our aim was to develop an optimal ischemic retinopathy mouse model to investigate the retinal damage in a time-dependent manner. Retinal ischemia was induced by bilateral common carotid artery occlusion (BCCAO) for 10, 13, 15 or 20 min, or by right permanent unilateral common carotid artery occlusion (UCCAO). Optical coherence tomography was used to follow the changes in retinal thickness 3, 7, 14, 21 and 28 days after surgery. The number of ganglion cells was evaluated in the central and peripheral regions on whole-mount retina preparations. Expression of glial fibrillary acidic protein (GFAP) was analyzed with immunohistochemistry and Western blot. Retinal degeneration and ganglion cell loss was observed in multiple groups. Our results suggest that the 20 min BCCAO is a good model to investigate the consequences of ischemia and reperfusion in the retina in a time-dependent manner, while the UCCAO causes more severe damage in a short time, so it can be used for testing new drugs.
- 23 July 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (15) , 8008
Open AccessOptimization of an Ischemic Retinopathy Mouse Model and the Consequences of Hypoxia in a Time-Dependent Manner
The retina is one of the highest metabolically active tissues with a high oxygen consumption, so insufficient blood supply leads to visual impairment. The incidence of related conditions is increasing; however, no effective treatment without side effects is available. Furthermore, the pathomechanism of these diseases is not fully understood. Our aim was to develop an optimal ischemic retinopathy mouse model to investigate the retinal damage in a time-dependent manner. Retinal ischemia was induced by bilateral common carotid artery occlusion (BCCAO) for 10, 13, 15 or 20 min, or by right permanent unilateral common carotid artery occlusion (UCCAO). Optical coherence tomography was used to follow the changes in retinal thickness 3, 7, 14, 21 and 28 days after surgery. The number of ganglion cells was evaluated in the central and peripheral regions on whole-mount retina preparations. Expression of glial fibrillary acidic protein (GFAP) was analyzed with immunohistochemistry and Western blot. Retinal degeneration and ganglion cell loss was observed in multiple groups. Our results suggest that the 20 min BCCAO is a good model to investigate the consequences of ischemia and reperfusion in the retina in a time-dependent manner, while the UCCAO causes more severe damage in a short time, so it can be used for testing new drugs.